Neoplasia/BPH

	Reply to Salvatore Cozzi and Thomas Zilli's, and Alexander Ho and Sean Sachdev's Letters to the Editor re: Markus Graefen, Fabian Falkenbach, Tobias Maurer, et al. Best Systemic Therapy With or Without Radical Prostatectomy in the Management of Men With Oligometastatic Prostate Cancer: The RAMPP Randomised Controlled Trial. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2025.09.4144. Eur Urol Falkenbach F, Beyer B, Graefen M. PMID: 41456981 [PubMed - as supplied by publisher]
	Assessing and Predicting Cutaneous Leiomyoma Severity in Hereditary Leiomyomatosis and Renal Cell Cancer Syndrome: An Observational Study. J Am Acad Dermatol Udupa M, Ouchene L, Bendayan E, Mija LA, Alamari A, Marino TC, Rahme E, Kaouache M, Foulkes WD, Netchiporouk E. PMID: 41456797 [PubMed - as supplied by publisher]
	Targeted therapies for urothelial carcinoma: From FGFR inhibitors to nextâ€‘generation antibody-drug conjugates (Review). Int J Oncol Du J, Shen H, Zeng T, Liu W, Xie Y. PMID: 41456439 [PubMed - indexed for MEDLINE]
	A Deep Learning-Based Multimodal Clinico-Histology-Genomic Prognostic Model in Prostate Cancer. Ann Surg Oncol Wu X, Zhou M, Zheng B, Lv S, Wei Q. PMID: 41456225 [PubMed - as supplied by publisher]
	Serum PSA levels fluctuations in patients with non-muscle-invasive bladder cancer (NMIBC) undergoing BCG therapy: a prospective study. BMC Urol Ahmadi SP, Sadabadi F, Khoshbin B, Sheikhi Z. PMID: 41455940 [PubMed - as supplied by publisher]
	Socioeconomic Status and Prostate-specific Antigen Testing: A Population-based Cohort Study Comparing Organised and Opportunistic Prostate Cancer Testing. Eur Urol Focus Arvendell M, Abbadi A, Phillips L, Crippa A, Nordström T, Lantz A. PMID: 41455654 [PubMed - as supplied by publisher]
	Diagnosis era-stratified analysis is important in the estimation of the risk of second primary cancer following renal cell carcinoma: reply to letter to the editor. Int Urol Nephrol Tundealao S, Okunlola P, Titiloye T, Mayungbo B, Adegbesan A, Sajja A, Olarewaju O. PMID: 41455067 [PubMed - as supplied by publisher]
	Explainable machine learning predicts overall survival in female bladder cancer patients after radical cystectomy. Discov Oncol Zhong MY, Zou XC, Chen PH. PMID: 41455036 [PubMed - as supplied by publisher]
	Post-HIFU surveillance of localized prostate cancer: role of PSMA-PET imaging versus the standard PSA-mpMRI protocol. World J Urol Mercier J, Bento L, Cassou-Mounat T, Prudhomme T, Lagarde S, Game X, Soulie M, Thoulouzan M, Bajeot AS, Roumiguie M. PMID: 41454965 [PubMed - indexed for MEDLINE]
	Application of computed diffusion-weighted imaging in vesical imaging reporting and data system assessment for bladder cancer. Abdom Radiol (NY) Zhang M, Chen C, Zeng X, Zhao Q, Cai W, Ma Z. PMID: 41454947 [PubMed - as supplied by publisher]
	Radical prostatectomy outcomes in patients with PI-RADS 5 lesions and favorable prostate cancer. World J Urol Charvet AL, Long Depaquit T, Bened H, Toledano H, Chemouni D, Daniel L, Bastide C, Baboudjian M. PMID: 41454938 [PubMed - indexed for MEDLINE]
	Global and local information-based prostate image registration of prostate-specific membrane antigen PET/CT and enhanced MRI. Med Phys Niu Y, Ma Z, Zhao H, Deng X, Xu D, Zou W. PMID: 41454834 [PubMed - indexed for MEDLINE]
	Magnetic Resonance Imaging-Transrectal Ultrasound Fusion-Targeted Biopsy Improves the Diagnostic Efficacy of Overall and Clinically Significant Prostate Cancer. Int J Urol Fukiage Y, Taga M, Inamura M, Kaeriyama K, Tanaka N, Seo W, Kakitsuba T, Shimada S, Okubo N, Kabuto T, Tsutsumiuchi M, Okumura Y, Muramoto A, Seki M, Inamura S, Terada N. PMID: 41454573 [PubMed - as supplied by publisher]
	Evaluation indicators for bladder dysfunction in Chinese patients following cervical cancer surgery: a Delphi study based on nursing outcomes classification. BMC Cancer Han X, Di R, Zhang H, Zhou B. PMID: 41454233 [PubMed - as supplied by publisher]
	Neoadjuvant pamiparib plus abiraterone and androgen deprivation therapy for high-risk/very high-risk localized prostate cancer: an open-label, single-arm, phase 2 study. Prostate Cancer Prostatic Dis Gong T, Liang S, Wu Z, Qiu X, Xu L, Peng S, Guo H, Zhang S, Zhuang J. PMID: 41454188 [PubMed - as supplied by publisher]
	Barriers and facilitators to prostate cancer healthcare in Black men in the UK: from diagnosis to survivorship. J Cancer Surviv Ettehad D, Mohammed H, Bailey JV, Schloss D, Walters K, Merriel SWD, Kinnaird W, Shaw G, Kirby M, Gopal DP, Huang Q, Baker H, Plackett R, Schartau P. PMID: 41454095 [PubMed - as supplied by publisher]
	Optimised comorbidity indices can reflect patient performance status in register based studies of prostate cancer. Sci Rep Westerberg M, Garmo H, Bonnedahl J, Eriksson MH, Robinson D, Stattin P, Gedeborg R. PMID: 41453947 [PubMed - as supplied by publisher]
	The value of PSMA PET for risk stratification in prostate cancer: an update and future aspects. Semin Nucl Med Civan C, Karpinski MJ, Rahbar K, Fendler WP, Herrmann K. PMID: 41453817 [PubMed - as supplied by publisher]
	Study design and methodologies for the men moving forward lifestyle intervention trial with black prostate cancer survivors. Contemp Clin Trials Awoyinka I, Stolley MR, Papanek P, Flynn KE, Bylow K, Kilari D, Gann P, Banerjee A, Sheean P. PMID: 41453520 [PubMed - as supplied by publisher]
	Tolerability of docetaxel in octogenarians with metastatic prostate cancer in the triplet therapy era: A single-center retrospective cohort study. J Geriatr Oncol Usui K, Suzuki A, Kubo H, Matsumoto T, Aigase T, Kishida T, Nakaigawa N. PMID: 41453269 [PubMed - as supplied by publisher]

Articles 1 - 20 / 184250

Page 1 of 9213



		Time frame

	Mediscope AG E-mail: info@mediscope.ch
	Disclaimer \| Privacy Policy